Pricing Log in Create free account

Carisma Therapeutics Inc. (CARM) vs GENPREX (GNPX)

Carisma Therapeutics Inc. and GENPREX are both Biotechnology companies. GENPREX is the larger, with a market value of $1.9M against $1.5M — 1.2× the size. Carisma Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; GENPREX trades at 0.0×. Carisma Therapeutics Inc. has the higher net margin (14.4% vs 0.00%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Carisma Therapeutics Inc. leads on 7 and GENPREX on 4.

Valuation

Metric CARM GNPX Biotechnology median
P/E n/m 0.03 8.50
P/S n/m n/m 9.71
P/B n/m 0.07 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.89 0.64
EV/Sales (0.05) n/m 9.21
Earnings yield 0.00% 3,170.61% (33.15%)
Free cash flow yield 0.00% (1,481.72%) (25.50%)

Profitability

Metric CARM GNPX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 19.36% 0.00% 0.00%
Net margin 14.36% 0.00% 0.00%
Free cash flow margin (38.79%) 0.00% 0.00%
Return on equity (134.11%) (203.86%) (56.36%)
Return on assets 33.09% (157.40%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CARM GNPX Biotechnology median
Revenue growth (TTM) 170.48% — 6.02%
EPS growth (last fiscal year) 43.68% 93.48% 30.26%
Revenue growth, 5-year CAGR 115.24% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CARM GNPX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.86 6.76 4.72
Net debt to EBITDA 0.30 0.50 0.96

Dividend

Metric CARM GNPX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CARM GNPX Biotechnology median
Market cap 1.52m 1.88m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack